JP5529754B2 - Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体 - Google Patents

Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体 Download PDF

Info

Publication number
JP5529754B2
JP5529754B2 JP2010539882A JP2010539882A JP5529754B2 JP 5529754 B2 JP5529754 B2 JP 5529754B2 JP 2010539882 A JP2010539882 A JP 2010539882A JP 2010539882 A JP2010539882 A JP 2010539882A JP 5529754 B2 JP5529754 B2 JP 5529754B2
Authority
JP
Japan
Prior art keywords
bmp
amino acid
modified
protein
noggin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010539882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507903A5 (enExample
JP2011507903A (ja
Inventor
ムーレイ ヒーシャム アラオウイ−イスメイリ，
キニング ソング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of JP2011507903A publication Critical patent/JP2011507903A/ja
Publication of JP2011507903A5 publication Critical patent/JP2011507903A5/ja
Application granted granted Critical
Publication of JP5529754B2 publication Critical patent/JP5529754B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010539882A 2007-12-21 2008-12-19 Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体 Expired - Fee Related JP5529754B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US875407P 2007-12-21 2007-12-21
US61/008,754 2007-12-21
PCT/US2008/087720 WO2009086131A1 (en) 2007-12-21 2008-12-19 Bmp mutants with decreased susceptibility to noggin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014056688A Division JP2014121334A (ja) 2007-12-21 2014-03-19 Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体

Publications (3)

Publication Number Publication Date
JP2011507903A JP2011507903A (ja) 2011-03-10
JP2011507903A5 JP2011507903A5 (enExample) 2013-01-17
JP5529754B2 true JP5529754B2 (ja) 2014-06-25

Family

ID=40424155

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010539882A Expired - Fee Related JP5529754B2 (ja) 2007-12-21 2008-12-19 Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
JP2014056688A Pending JP2014121334A (ja) 2007-12-21 2014-03-19 Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014056688A Pending JP2014121334A (ja) 2007-12-21 2014-03-19 Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体

Country Status (6)

Country Link
US (2) US20110039773A1 (enExample)
EP (1) EP2222696A1 (enExample)
JP (2) JP5529754B2 (enExample)
AU (1) AU2008345689B2 (enExample)
CA (1) CA2708549C (enExample)
WO (1) WO2009086131A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698691A1 (en) * 2005-03-04 2006-09-06 Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH Growth factor mutants with improved biological activity
US20110039773A1 (en) * 2007-12-21 2011-02-17 Stryker Biotech BMP Mutants with Decreased Susceptibility to Noggin
AU2010223268B2 (en) * 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
CN102822197A (zh) * 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
AU2015202418B2 (en) * 2010-08-20 2017-02-02 Wyeth Llc Designer osteogenic proteins
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
RU2013104029A (ru) 2010-08-20 2014-09-27 ВАЙЕТ ЭлЭлСи Сконструированные остеогенные белки
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
AU2015294371B2 (en) * 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
MX387317B (es) 2015-05-01 2025-03-18 Onl Therapeutics Inc Composiciones de peptido y metodos de uso.
EP3500585A4 (en) 2016-08-17 2020-04-01 Factor Bioscience Inc. NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
BR112019022566A2 (pt) 2017-04-27 2020-05-19 Lilly Co Eli variantes da proteína bmp7 humana

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7459527B2 (en) * 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
JP2008509087A (ja) * 2004-05-27 2008-03-27 アクセルロン ファーマ インコーポレーテッド Ｔｇｆ抑制解除因子およびそれに関連する使用方法
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
US20110039773A1 (en) * 2007-12-21 2011-02-17 Stryker Biotech BMP Mutants with Decreased Susceptibility to Noggin

Also Published As

Publication number Publication date
US20130184208A1 (en) 2013-07-18
WO2009086131A4 (en) 2009-09-11
CA2708549A1 (en) 2009-07-09
CA2708549C (en) 2014-04-01
EP2222696A1 (en) 2010-09-01
JP2014121334A (ja) 2014-07-03
WO2009086131A1 (en) 2009-07-09
AU2008345689A1 (en) 2009-07-09
AU2008345689B2 (en) 2013-04-18
JP2011507903A (ja) 2011-03-10
US20110039773A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
JP5529754B2 (ja) Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
TWI444475B (zh) 經設計之成骨蛋白類
US20160060319A1 (en) Development of Protein-Based Biotherapeutics That Induced Osteogenesis for Bone Healing Therapy: Cell-Permeable BMP2 and BMP7 Recombinant Proteins (CP-BMP2 & CP-BMP7), Polynucleotides Encoding the Same and Pro-osteogenic Compositions Comprising the Same
US20160376334A1 (en) Positive modulator of bone morphogenic protein-2
JP2008500816A (ja) 改善された性質を有するｂｍｐ−７変異体
DE69333745T2 (de) Löslicher komplex morphogener proteine und zusammensetzungen davon
US20100183719A1 (en) Surgical Applications for BMP Binding Protein
TW202203961A (zh) 用於遞送靶向治療劑至骨骼之組合物及方法
CA2774024A1 (en) Buffers for controlling the ph of bone morphogenetic proteins
WO2008051526A9 (en) Bone morphogenetic proteins
Kang et al. Cell-permeable bone morphogenetic protein 2 facilitates bone regeneration by promoting osteogenesis
ES2382464T3 (es) Mutantes de factor del crecimiento de actividad elevada
US20130190236A1 (en) BMP-7 Variants with Reduced Immunogenicity
US9012401B2 (en) Growth factor mutants with improved biological activity
CN107636008B (zh) 改进的成骨蛋白
Dreyer Effect of recombinant mouse sclerostin proteins on bone formation in vitro and in a murine model of sclerosteosis
Lowery et al. Bone Morphogenetic Protein-Based Therapeutic Approaches.
AU2018236821A1 (en) Designer osteogenic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140417

R150 Certificate of patent or registration of utility model

Ref document number: 5529754

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees